BioSpace News Archive

Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studies In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD 1 TOKYO &

Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it adjourned its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m.,

Scopus BioPharma Inc. (“Scopus” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting serious diseases with significant unmet medical needs, today announced the signing of an exclusive, worldwide license to a novel, first-in-class, targeted immuno-oncology gene therapy drug developed at City of Hope.

Mirum Pharmaceuticals, Inc. announced that the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of common stock to two new employees under Mirum’s 2020 Inducement Plan.

Almirall, S.A. (Madrid: ALM), a global pharmaceutical company focused on skin health, has been selected by the IBEX Technical Advisory Committee (CAT) to join the IBEX 35, the benchmark stock market index of the Bolsa de Madrid, Spain’s principal stock exchange.

City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, has signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc., a biopharmaceutical company focused on novel therapeutics for serious diseases with significant unmet medical needs.

During the height of the pandemic, one small NJ hospital, Long-Term Acute Care Specialty Hospital of Central Jersey, accepted critical COVID-19 patients from hospitals in 4 states and reports High COVID-19 recovery success!

While studying the effects of androgens on hair loss, Applied Biology scientists discovered an association between baldness (androgenetic alopecia) and the risk of COVID-19 disease severity.

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Semglee™

CRH Medical Corporation, announces the following voting results for the Company’s 2020 Annual General Meeting of Shareholders.